Paper - WANFANG MED ONLINE

You Position: Home > Paper

Selection and clinical significance of individualized treatment for metastatic liver cancer

( views:31, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 29

DOI:: 10.11569/wcjd.v26.i29.1677

Key Word:: 转移性肝癌;个体化治疗;临床意义

Abstract：肝脏是恶性肿瘤转移最常见的靶器官之一,转移率为11.1％;恶性肿瘤患者40％出现肝转移.转移性肝癌不仅在原发肿瘤来源、肿瘤基因和生物学行为等方面存在个体化差异,而且在肿瘤进展阶段、解剖学特点、机体功能、并发症等方面亦存在差异.针对转移肿瘤来源和途径不同,转移性肝癌治疗涉及原发肿瘤和肝转移肿瘤两个方面,如何合理选择手术、局部消融、化疗、分子靶向药物、内分泌、生物免疫、放射等治疗方法及治疗时机,是转移性肝癌治疗的关键.利用现代先进的影像学技术明确转移性肝癌肿瘤大小、数目、部位、血供等情况,为精确制定转移性肝癌个体化治疗方案提供客观依据.目前任何一种治疗转移性肝癌的方法均有其各自的适应证,对于不能手术根治切除的转移性肝癌,单一治疗方法难以达到治愈或控制肿瘤进展,需要两种或两种以上治疗方法有机地联合,达到协同增效的治疗效果.依据患者的具体情况,分析其个体特性,结合临床医生的临床经验和最佳证据,制定出符合循证医学原则的个体化治疗方案,才能使转移性肝癌患者最大程度获益,改善患者生存质量,延长生存期.

Reference

[1]秦建民,顾新刚,张敏,等.肝脏实时超声造影在肝癌微波消融治疗中的应用[J].2013,(1).
[2]张华锋,赵佳,刘新颖.转移性肾细胞癌靶向药物治疗长期疗效观察[J].2015,(7).
[3]中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠肛门外科学组,中国抗癌协会大肠癌专业委员会,等.结直肠癌肝转移诊断和综合治疗指南（2016版）[J].2016,(8).
[4]刘德华,华阳,王少雷,等.肝动脉栓塞化疗与灌注化疗介入治疗结肠癌肝转移瘤的临床研究[J].2006,(3).
[5]丁莺,曾蒙苏,饶圣祥,等.肝细胞特异性对比剂普美显对结直肠癌肝转移的显示能力研究[J].2014,(6).
[6]王凤山,刘永锋.转移性肝癌的治疗[J].2008,(2).
[7]秦建民,顾新刚,王之,等.原发性肝癌术后复发或转移性肝癌微创治疗的指征与临床处理[J].2016,(5).
[8]冉琳,陈鹏,彭勤中,等.经皮超声引导下125I粒子植入治疗肝脏肿瘤[J].2010,(6).
[9]陆若飞,施海辉,黄桃辉.经肝动脉灌注化疗栓塞术与单纯肝动脉灌注术对胃癌肝转移瘤的疗效对比[J].2015,(1).
[10]孟泽武,陈燕凌,朱金海,等.胰腺癌术后肝转移的治疗策略及预后分析[J].2015,(1).
[11]肖越勇,张欣.纳米刀消融技术在肝癌中的应用[J].2015,(2).
[12]王红治,赵子粼,罗敏,等.超声引导经皮微波消融治疗肝癌的个体化方案及疗效[J].2012,(11).
[13]何雪琦,孙力军,王军业.动脉化疗栓塞术联合微波消融及静脉化疗治疗消化道肿瘤肝转移临床观察[J].2014,(6).
[14]崔红凯,李奋保,张铭秋,等.CT引导下冷循环微波刀治疗转移性肝癌的疗效分析[J].2010,(29).
[15]王萍.B超在诊断转移性肝癌的临床价值[J].2011,(7).
[16]韩浩,陈敏华,杨薇,等.肝细胞癌射频消融后局部肿瘤进展多因素分析[J].2012,(2).
[17]李红梅,代晓强.XELOX方案化疗联合微波消融治疗胃癌术后肝转移疗效分析[J].2017,(1).
[18]冯字清,苏加利,蔡薇薇,等.TACE联合体部伽玛刀放疗与手术治疗大肠癌肝转移的疗效比较[J].2017,(1).
[19]辛崇尚,相成,潘兆随,等.肝转移瘤血管造影影像分析及介入治疗[J].2011,(10).
[20]周春泽,吕维富,张行明,等.选择性门静脉栓塞术联合肝动脉化疗栓塞术治疗肝转移癌的对照研究[J].2012,(5).
[21]张崇高,王国林,穆四清.微波消融联合TACE治疗结肠癌肝转移[J].2012,(6).
[22]李金鹏,宋金龙.甲磺酸伊马替尼联合肝动脉化疗栓塞术治疗胃肠间质瘤肝转移的疗效观察[J].2012,(6).
[23]徐凡,郭媛,吴梅,等.320层螺旋CT动态增强扫描对影像学表现不典型转移性肝癌的诊断价值[J].2015,(2).
[24]李智岗,黄景香,李顺宗,等.肝转移瘤的血供[J].2008,(2).
[25]岳健,马飞,张灵小,等.卡培他滨联合多西他赛或长春瑞滨治疗乳腺癌肝转移的临床观察及疗效分析[J].2013,(21).
[26]翟博,陈夷,刘晟,等.原发性肝癌射频消融后肿瘤残留分析[J].2009,(4).
[27]熊奎,况建荣,李超,等.三维适形技术在射频消融治疗原发性肝癌中的应用[J].2005,(8).
[28]伍松,杨志明,张君莉,等.超声引导PMCT联合阿帕替尼治疗转移性肝癌的临床评价[J].2017,(9).
[29]Sandstrom, Per,Rosok, Bard I.,Sparrelid, Ernesto,etc.ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)[J].2018,267(5).
[30]Lin G,Hagerstrand I,Lunderquist A.Portal blood supply of liver metastases[J].1984.
[31]Farrell, Ann T.,Pazdur, Richard,Mehrotra, Nitin,etc.FDA Approval: Blinatumomab[J].2015,21(18).
[32]Sharma, DAYA Nand,Thulkar, Sanjay,Sharma, Seema,etc.High-dose-rate interstitial brachytherapy for liver metastases: first study from India.[J].2013,5(2).
[33]Meisetschlaeger G,Rummeny EJ,Gaa J,etc.Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.[J].2006,11(2).
[34]郭晓光,王虎明.替吉奥联合TACE序贯肝动脉灌注奥沙利铂治疗转移性肝癌的临床研究[J].2015,(5).
[35]王洋洋,王振光,李大成,等.18F-FDG PET/CT诊断原发性肝癌和肝转移瘤的价值[J].2015,(1).
[36]M, Makuuchi,B L, Thai,K, Takayasu,etc.Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.[J].1990,107.
[37]Disibio G,French SW.Metastatic patterns of cancers: results from a large autopsy study.[J].2008,132(6).
[38]瞿霏霏,黄伟谦,张闯,等.树突状细胞疫苗联合射频消融术治疗结直肠癌肝转移临床疗效[J].2016,(1).
[39]Moris, Dimitrios,Tsilimigras, Diamantis I.,Ntanasis-Stathopoulos, Ioannis,etc.Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review[J].2017,162(3).
[40]Erik Schadde,Victoria Ardiles,Ricardo Robles-Campos,etc.Early survival and safety of ALPPS: first report of the International ALPPS Registry.[J].2014,260(5).
[41]Hang, Yin,Kai, Lu,Wen-Bo, Qiao,etc.Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study.[J].2014,15.
[42]Treska V,Ferda J,Skalicky T,etc.Repeated procedures for colorectal liver metastases.[J].2007,54(78).
[43]Bang YJ,Van Cutsem E,Feyereislova A,etc.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.[J].2010,376(9742).
[44]Lisa A, Raedler.Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma.[J].2015,8.
[45]Flies,D.B.,Chen,L..Molecular mechanisms of T cell co-stimulation and co-inhibition[J].2013,13(4).
[46]Wang YF,Yu H,Peng SY,etc.Clinical study of laparoscopic versus open hepatectomy for malignant liver tumors.[J].2008,22(11).
[47]刘宏云,臧歆,吴建华,等.CT导向下经皮无水酒精消融治疗乏血性肝转移瘤[J].2005,002 (9).
[48]淡绪国,孔玉莲,王玉,等.胃癌肝转移介入治疗效果分析[J].2013,(21).
[49]Tumeh, Paul C.,Hellmann, Matthew D.,Hamid, Omid,etc.Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC[J].2017,5(5).
[50]Castaing D,Vibert E,Ricca L.Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers.[J].2009,250(5).
[51]Brown, Christine E.,Alizadeh, Darya,Starr, Renate,etc.Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy[J].2016,375(26).
[52]Woubet Tefera Kassahun.Controversies in defining prognostic relevant selection criteria that determine long-term effectiveness of liver resection for noncolorectal nonneuroendocrine liver metastasis[J].2015,24.
[53]唐裕福,张怡冰,罗斌,等.肿瘤残余在肝癌微波消融治疗后出现的原因及防治[J].2011,(10).
[54]Norihiro Kokudo,Keiichiro Tada,Makoto Seki,etc.Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization[J].2001,34(2).
[55]Groeschl, Ryan T.,Pilgrim, Charles H. C.,Hanna, Erin M.,etc.Microwave Ablation for Hepatic Malignancies A Multiinstitutional Analysis[J].2014,259(6).
[56]Kim JJ,Ringash J,Tse RV,etc.Phase I study of individualized stereotactic body radiotherapy of liver metastases.[J].2009,27(10).
[57]H, Liu,D, Li,S, Yang,etc.[Changes of blood supply from portal system after transcatheter arterial chemoembolization in huge hepatocellular carcinoma].[J].1998,23(3).
[58]T, Yamasaki,F, Kurokawa,H, Shirahashi,etc.Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma.[J].2001,91(7).
[59]Clarke, Ellen,Coffin, Robert.Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer[J].2016,8(2).
[60]P, Della Vigna,F, Cernigliaro,L, Monfardini,etc.Contrast-enhanced ultrasonography in the follow-up of patients with hepatic metastases from breast carcinoma.[J].2007,112(1).
[61]L, Vlachos,S, Trakadas,A, Gouliamos,etc.Comparative study between ultrasound, computed tomography, intra-arterial digital subtraction angiography, and magnetic resonance imaging in the differentiation of tumors of the liver.[J].1990,15(2).
[62]Valle J,Mudan S,Hickish T,etc.A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.[J].2011,22(9).
[63]Dueland S.,Foss A.,Solheim J. M.,etc.Survival following liver transplantation for liver‐only colorectal metastases compared with hepatocellular carcinoma[J].2018,105(6).
[64]Finn,O.J..Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer[J].2012,23(Suppl.8).
[65]Cheever MA,Higano CS.PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.[J].2011,17(11).
[66]Gena P, Kanas,Aliki, Taylor,John N, Primrose,etc.Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.[J].2012,4.
[67]申丽君,章真.放疗在结直肠癌肝转移治疗中的价值[J].2016,(4).
[68]Katz, Steven C.,Burga, Rachel A.,McCormack, Elise,etc.Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA(+) Liver Metastases[J].2015,21(14).
[69]Gregory L, Beatty,Andrew R, Haas,Marcela V, Maus,etc.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.[J].2014,2(2).
[70]Marta, Scorsetti,Elena, Clerici,Tiziana, Comito.Stereotactic body radiation therapy for liver metastases.[J].2014,5(3).
[71]Raewyn M Poole.Pembrolizumab: first global approval.[J].2014,74(16).
[72]Fellne,C..Ipilimumab (Yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use[J].2012,37(9).
[73]Galeotti F,Cordiano C,Rampin L,etc.Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study.[J].2010,12(2).
[74]Emanuele, Felli,Roberto, Santoro,Marco, Colasanti,etc.Robotic liver surgery: preliminary experience in a tertiary hepato-biliary unit.[J].2015,67(1).
[75]Schnitzbauer,A.A.,Lang,S.A.,Goessmann,H.,etc.Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J].2012,255(3).
[76]Batlevi, Connie Lee,Matsuki, Eri,Brentjens, Renier J.,etc.Novel immunotherapies in lymphoid malignancies[J].2016,13(1).
[77]Parks,K.R.,Kuo,Y.-H.,Davis,J.M.,etc.Laparoscopic versus open liver resection: A meta-analysis of long-term outcome[J].2014,16(2).
[78]Hori S,Seki A.Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.[J].2011,16(5).
[79]Calista Spiro,Emma Johnston,Michael J Hollands,etc.A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.[J].2012,19(4).
[80]Le-Chi Ye,Tian-Shu Liu,Li Ren,etc.Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.[J].2013,31(16).